SCHEMBL1978520

SCHEMBL1978520

NCC(c1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.68
HTR2A P28223 2/20 0.59
TAAR1 Q96RJ0 1/20 0.59
AKT2 P31751 3/20 0.58
CHRNB2 P17787 1/20 0.54
CHRNA4 P43681 1/20 0.54
GABBR2 O75899 6/20 0.53
GABBR1 Q9UBS5 6/20 0.53
LMNA P02545 3/20 0.53
CYP2C9 P11712 2/20 0.53
CYP1A2 P05177 2/20 0.53
THRB P10828 2/20 0.53
CYP3A4 P08684 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
NFKB1 P19838 1/20 0.53
DRD3 P35462 1/20 0.53
BLM P54132 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C19 P33261 1/20 0.53
MEN1 O00255 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3525702 0.97 CHRNA7 (0.66) CHRNA7HTR2ATAAR1AKT2CHRNB2
SCHEMBL21068075 0.93 HTR2A (0.73) CHRNA7HTR2ATAAR1AKT2CHRNB2
SCHEMBL1979244 0.93 HTR2A (0.73) CHRNA7HTR2ATAAR1AKT2CHRNB2
Hydrochloric Acid SCHEMBL1977273 0.91 CHRNA7 (0.70) CHRNA7HTR2ATAAR1AKT2CHRNB2
SCHEMBL4619055 0.80 HRH1 (0.62) CHRNA7HTR2ATAAR1AKT2GABBR2
SCHEMBL10507284 0.79 GABBR2 (0.64) CHRNA7GABBR2GABBR1LMNACYP2C9
SCHEMBL3317983 0.77 TSHR (0.48) CHRNA7TAAR1AKT2GABBR2GABBR1
Hydrochloric Acid SCHEMBL10681987 0.77 GABBR2 (0.62) CHRNA7GABBR2GABBR1LMNACYP2C9
SCHEMBL3702383 0.77 TSHR (0.48) CHRNA7TAAR1AKT2GABBR2GABBR1
SCHEMBL1953110 0.77 ADRB2 (0.52) CHRNA7AKT2GABBR2GABBR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160250187-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS ASTEX THERAPEUTICS LTD (GB) 2016-09-01 US disclosed
US-9283226-B2 Pyrazole derivatives as protein kinase modulators ASTEX THERAPEUTICS LIMITED (GB) 2016-03-15 US disclosed
US-20140271662-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS ASTEX THERAPEUTICS LTD (GB) 2014-09-18 US disclosed
US-8541461-B2 Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators ASTEX THERAPEUTICS LIMITED (GB) 2013-09-24 US disclosed
US-20130005702-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2013-01-03 US disclosed
US-8343953-B2 Pharmaceutical compounds ASTEX THERAPEUTICS LIMITED (GB) 2013-01-01 US disclosed
US-8247576-B2 Pyrazole derivatives as protein kinase modulators ASTEX THERAPEUTICS LIMITED (GB) 2012-08-21 US disclosed
US-20110144080-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2011-06-16 US disclosed
US-7855292-B2 Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics JANSSEN PHARMACEUTICA NV (BE) 2010-12-21 US disclosed
US-20100292240-A1 SULFONAMIDE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US disclosed
EP-1069132-A1 Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them ADIR ET COMPAGNIE (FR) 2001-01-17 EP disclosed
US-6150335-A TREATMENT FOR PAIN ASTRA AB (SE) 2000-11-21 US disclosed
EP-0946588-A1 USE OF DIPEPTIDE DERIVATIVES Astra Aktiebolag (publ) (SE) 1999-10-06 EP disclosed
WO-1998028327-A1 NEW USE OF DIPEPTIDE DERIVATIVES ASTRA AKTIEBOLAG (PUBL) (SE) 1998-07-02 WO disclosed
EP-0139358-B1 N6-SUBSTITUTED DIARYLALKYL ADENOSINES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME WARNER-LAMBERT COMPANY (US) 1988-11-09 EP disclosed
EP-0251339-A2 N6- substituted diarylalkyl adenosines, processes for their production and pharmaceutical compositions comprising the same WARNER-LAMBERT COMPANY (US) 1988-01-07 EP disclosed
US-4657898-A CARDIOVACULAR AND PSYCHOLOGICAL DISORDERS, ANALGESICS, OR SEDATIVES WARNER-LAMBERT COMPANY (US) 1987-04-14 US disclosed
US-4657897-A N6 -substituted adenosines for treating pain WARNER-LAMBERT COMPANY (US) 1987-04-14 US disclosed
US-4649204-A ANTIDEPRESSANTS MCNEILAB, INC. (US) 1987-03-10 US disclosed
EP-0139358-A2 N6-substituted diarylalkyl adenosines, processes for their production and pharmaceutical compositions comprising the same WARNER-LAMBERT COMPANY (US) 1985-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144080-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS GRK3, GRK2, NR0B2 CHRNA7 1844/4885HTR2A 907/4885TAAR1 1660/4885
US-20130005702-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS PRKCB, MAP3K19, MAP4K2 CHRNA7 4099/4885HTR2A 3715/4885TAAR1 4623/4885
US-20140271662-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS GRK3, GRK2, NR0B2 CHRNA7 1717/4885HTR2A 862/4885TAAR1 1702/4885
US-20100292240-A1 SULFONAMIDE COMPOUNDS CCKAR, CCKBR, TAS1R2 CHRNA7 4748/4885HTR2A 860/4885TAAR1 2804/4885
US-20160250187-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS GRK3, GRK2, NR0B2 CHRNA7 1717/4885HTR2A 862/4885TAAR1 1702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.